5. 進行性核上性麻痺 Disease details / Clinical trials / Drug dev / DR info

11C-PIB
   Nagoya City Rehabilitation Agency
      2019   -   JPRN-UMIN000036956   Japan
      2019   -   JPRN-UMIN000036908   Japan
11C-raclopride
   Nagoya City Rehabilitation Agency
      2019   -   JPRN-UMIN000036952   Japan
13c6 leucine
   Washington University School of Medicine
      2017   -   NCT03545126   United States
18F-AV-1451
   Skåne University Hospital, Region Skåne
      2014   Phase 2   EUCTR2014-000422-38-SE   Sweden
18F-FDG
   Nagoya City Rehabilitation Agency
      2019   -   JPRN-UMIN000036908   Japan
18F-RO6958948
   Skåne University Hospital
      2017   Phase 2   EUCTR2017-000094-36-SE   Sweden
4-benzyl-2-naphtalen-1-YL-1,2,4-thiadiazolidine-3,5-dione
   Noscira S.A.
      2009   Phase 2   EUCTR2009-013097-40-GB   Germany;Spain;United Kingdom
      2009   -   EUCTR2009-013097-40-ES   Germany;Spain;United Kingdom
      2009   -   EUCTR2009-013097-40-DE   Germany;Spain;United Kingdom
9-CIS, 12-CIS-11,11-D2-linoleic acid ethyl ester
   Retrotope, Inc
      2021   Phase 2   EUCTR2020-003911-90-SK   Germany;Hungary;Poland;Slovakia
      2021   Phase 2   EUCTR2020-003911-90-PL   Germany;Hungary;Poland;Slovakia
      2021   Phase 2   EUCTR2020-003911-90-HU   Germany;Hungary;Poland;Slovakia
      2021   Phase 2   EUCTR2020-003911-90-DE   Germany;Hungary;Poland;Slovakia
AB1010
   AB Science
      2015   Phase 3   EUCTR2013-003740-23-ES   Spain
ABBV-8e12
   ABBVIE DEUTSCHLAND GMBH & CO. KG
      2018   Phase 2   EUCTR2017-001590-16-IT   Australia;Canada;Germany;Italy;United States
      2017   Phase 2   EUCTR2016-001635-12-IT   Australia;Canada;Italy;United States
   AbbVie
      2018   Phase 1   NCT03413319   United States
      2018   Phase 2   NCT03391765   Australia;Canada;France;Italy;Japan;United States
      2016   Phase 2   NCT02985879   Australia;Canada;France;Germany;Italy;Japan;Spain;United States
   AbbVie Deutschland
      2019   Phase 2   EUCTR2017-001590-16-DE   Australia;Canada;Germany;United States
   AbbVie Deutschland GmbH & Co. KG
      2018   Phase 2   EUCTR2016-001635-12-ES   Australia;Canada;Germany;Italy;Spain;United States
      2017   Phase 2   EUCTR2016-001635-12-FR   Australia;Canada;France;Germany;Italy;Spain;United States
      2017   Phase 2   EUCTR2016-001635-12-DE   Australia;Canada;Germany;Italy;Spain;United States
AL-108
   Allon Therapeutics Inc
      2010   Phase 2;Phase 3   EUCTR2010-019159-23-GB   Australia;Canada;France;Germany;United Kingdom;United States
      2010   -   EUCTR2010-019159-23-DE   Australia;Canada;France;Germany;United Kingdom;United States
   University of California, San Francisco
      2010   Phase 1   NCT01056965   United States
Alpha-lipoic acid and L-acetyl carnitine
   Weill Medical College of Cornell University
      2010   Phase 1/Phase 2   NCT01537549   United States
AMX0035
   Amylyx Pharmaceuticals Inc.
      2023   Phase 2/Phase 3   NCT06122662   France;Germany;Italy;Spain;United States
ANTI-parkinson medication
   Beth Israel Deaconess Medical Center
      2016   -   NCT02994719   United States
Antisense oligonucleotide
   Novartis Pharmaceuticals
      2021   Phase 1   NCT04539041   Canada;Germany;United Kingdom;United States
Apomorphine
   Fondation Ophtalmologique Adolphe de Rothschild
      2018   -   NCT04786158   France
ASK NR. 21972
   Kompetenznetz Parkinson e.V.
      2006   -   EUCTR2005-000574-40-DE   Germany
Azilect
   Klinikum der Universität München
      2010   -   EUCTR2008-007520-26-DE   Germany
AZP2006 oral solution
   AlzProtect SAS
      2020   Phase 2   NCT04008355   France
Bepranemab
   UCB Biopharma SRL
      2020   Phase 1   NCT04658199   Belgium;Germany;Spain;United Kingdom
      2019   Phase 1   NCT04185415   Belgium;Germany;Spain;United Kingdom
BIIB092
   BIOGEN IDEC RESEARCH LIMITED
      2018   Phase 2   EUCTR2016-002554-21-IT   Australia;Austria;Canada;France;Germany;Greece;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;United Kingdom;United States
   Biogen
      2017   Phase 2   NCT03068468   Australia;Austria;Canada;France;Germany;Greece;Italy;Japan;Korea, Republic of;Russian Federation;Spain;United Kingdom;United States
      2016   Phase 1   NCT02658916   United States
      2015   Phase 1   NCT02460094   United States
   Biogen Idec Research Limited
      2018   Phase 2   EUCTR2016-002554-21-GR   Australia;Austria;Canada;France;Germany;Greece;Italy;Japan;Korea, Republic of;Russian Federation;Spain;United Kingdom;United States
      2017   Phase 2   EUCTR2016-002554-21-GB   Australia;Austria;Canada;France;Germany;Greece;Italy;Japan;Korea, Republic of;Russian Federation;Spain;United Kingdom;United States
      2017   Phase 2   EUCTR2016-002554-21-DE   Australia;Austria;Canada;France;Germany;Greece;Italy;Japan;Korea, Republic of;Russian Federation;Spain;United Kingdom;United States
      2017   Phase 2   EUCTR2016-002554-21-AT   Australia;Austria;Canada;France;Germany;Greece;Italy;Japan;Korea, Republic of;Russian Federation;Spain;United Kingdom;United States
BMS-986168
   Bristol-Myers Squibb International Corporation
      2017   Phase 2   EUCTR2016-002554-21-ES   Australia;Austria;Canada;France;Germany;Greece;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;United Kingdom;United States
      -   Phase 2   EUCTR2016-002554-21-FR   Australia;Austria;Canada;France;Germany;Greece;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;United Kingdom;United States
   Bristol-Myers Squibb K.K.
      2017   Phase 2   JPRN-jRCT2080223571   -
BMS986168
   Bristol-Myers Squibb International Corporation
      2017   Phase 2   EUCTR2016-002554-21-ES   Australia;Austria;Canada;France;Germany;Greece;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;United Kingdom;United States
      -   Phase 2   EUCTR2016-002554-21-FR   Australia;Austria;Canada;France;Germany;Greece;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;United Kingdom;United States
Botulinum toxin type A
   Merz Pharmaceuticals GmbH
      2014   Phase 3   EUCTR2012-005539-10-DE   Germany;Poland;United States
Brain PET scan
   Avid Radiopharmaceuticals
      2014   Phase 1   NCT02167594   United States
Coenzym Q10 nanodispersion
   Kompetenznetz Parkinson e.V.
      2006   -   EUCTR2005-000574-40-DE   Germany
Coenzym Q10, ubiquinon, ubichinon
   Kompetenznetz Parkinson e.V.
      2006   -   EUCTR2005-000574-40-DE   Germany
Coenzyme Q10
   German Parkinson Study Group (GPS)
      2006   Phase 2   NCT00328874   Germany
   Lahey Clinic
      2006   -   NCT00382824   United States
COQ10
   Lahey Clinic
      2004   Phase 2/Phase 3   NCT00532571   United States
Datscan
   Molecular NeuroImaging
      2016   Early Phase 1   NCT03058965   United States
Davunetide
   Allon Therapeutics
      2010   Phase 2/Phase 3   NCT01110720   Australia;Canada;France;Germany;United Kingdom;United States
   Allon Therapeutics Inc
      2010   Phase 2;Phase 3   EUCTR2010-019159-23-GB   Australia;Canada;France;Germany;United Kingdom;United States
      2010   -   EUCTR2010-019159-23-DE   Australia;Canada;France;Germany;United Kingdom;United States
   University of California, San Francisco
      2010   Phase 1   NCT01056965   United States
Deep brain stimulation
   Beth Israel Deaconess Medical Center
      2016   -   NCT02994719   United States
Donepezil
   Groupe Hospitalier Pitie-Salpetriere
      2005   Phase 2   NCT00139373   France
Droxidopa
   Loma Linda University
      2021   Phase 2   NCT03446807   United States
Elecsys (roche) abeta42, ttau and ptau
   Skane University Hospital
      2017   -   NCT03174938   Sweden
Emeramide
   NBMI Science Ltd.
      2019   Phase 2   EUCTR2018-000506-34-SI   Slovenia
Exelon 1,5 MG hartkapseln
   University of Tuebingen
      2007   -   EUCTR2006-006166-42-DE   Germany
Exelon 3,0 MG hartkapseln
   University of Tuebingen
      2007   -   EUCTR2006-006166-42-DE   Germany
Exelon 6,0 MG hartkapseln
   University of Tuebingen
      2007   -   EUCTR2006-006166-42-DE   Germany
F-18
   Chang Gung Memorial Hospital
      2018   Early Phase 1   NCT03625128   Taiwan
   Skåne University Hospital
      2017   Phase 2   EUCTR2017-000094-36-SE   Sweden
F-18 AV 1451
   Mayo Clinic
      2015   -   NCT02605785   United States
Fasudil
   Woolsey Pharmaceuticals
      2021   Phase 2   NCT04734379   United States
FDG-PET
   Itoh Yoshiaki
      2019   -   JPRN-jRCTs051180214   -
Flortaucipir F18
   Avid Radiopharmaceuticals
      2014   Phase 1   NCT02167594   United States
Flutemetamol
   Itoh Yoshiaki
      2019   -   JPRN-jRCTs051180214   -
   Skåne University Hospital
      2017   Phase 2   EUCTR2017-000094-36-SE   Sweden
Flutemetamol F18 injection
   Skane University Hospital
      2017   -   NCT03174938   Sweden
FNP-223
   Ferrer Internacional S.A.
      2024   Phase 2   NCT06355531   France;Germany;Hungary;Italy;Poland;Portugal;Spain;United Kingdom;United States
Fresh frozen plasma
   University of California, San Francisco
      2015   Phase 1   NCT02460731   United States
Gdnf & synchro MED infusion system
   National Institute of Neurological Disorders and Stroke (NINDS)
      2000   Phase 2   NCT00005903   United States
GV1001 0.56MG
   GemVax & Kael
      2023   Phase 2   NCT05819658   Korea, Republic of
GV1001 1.12MG
   GemVax & Kael
      2023   Phase 2   NCT06235775   Korea, Republic of
      2023   Phase 2   NCT05819658   Korea, Republic of
Hydrogen
   Juntendo University School of Medicine, Department of Neurology
      2012   Phase 1   JPRN-UMIN000008959   Japan
Injection
   BIOGEN IDEC RESEARCH LIMITED
      2018   Phase 2   EUCTR2016-002554-21-IT   Australia;Austria;Canada;France;Germany;Greece;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;United Kingdom;United States
   Kagawa University
      2021   -   JPRN-UMIN000043737   Japan
   Merz Pharmaceuticals GmbH
      2014   Phase 3   EUCTR2012-005539-10-DE   Germany;Poland;United States
   Skåne University Hospital
      2017   Phase 2   EUCTR2017-000094-36-SE   Sweden
   Skåne University Hospital, Region Skåne
      2014   Phase 2   EUCTR2014-000422-38-SE   Sweden
Lithium
   Westat
      2008   Phase 1/Phase 2   NCT00703677   United Kingdom;United States
Lumipulse (fujirebio) abeta42, ttau and ptau
   Skane University Hospital
      2017   -   NCT03174938   Sweden
Masitinib 100MG
   AB Science
      2015   Phase 3   EUCTR2013-003740-23-ES   Spain
Masitinib 200MG
   AB Science
      2015   Phase 3   EUCTR2013-003740-23-ES   Spain
Masitinib mesylate
   AB Science
      2015   Phase 3   EUCTR2013-003740-23-ES   Spain
N1,N3-BIS(2-mercaptoethyl) isophthalamide
   NBMI Science Ltd.
      2019   Phase 2   EUCTR2018-000506-34-SI   Slovenia
Nbmi
   EmeraMed
      2019   Phase 2   NCT04184063   Slovenia
   NBMI Science Ltd.
      2019   Phase 2   EUCTR2018-000506-34-SI   Slovenia
Nicotinamide riboside
   Haukeland University Hospital
      2024   Phase 2   NCT06162013   Norway
Nitrogen
   Juntendo University School of Medicine, Department of Neurology
      2012   Phase 1   JPRN-UMIN000008959   Japan
NP031112 600MG
   Noscira S.A.
      2009   Phase 2   EUCTR2009-013097-40-GB   Germany;Spain;United Kingdom
      2009   -   EUCTR2009-013097-40-ES   Germany;Spain;United Kingdom
      2009   -   EUCTR2009-013097-40-DE   Germany;Spain;United Kingdom
NP031112 800MG
   Noscira S.A.
      2009   Phase 2   EUCTR2009-013097-40-GB   Germany;Spain;United Kingdom
      2009   -   EUCTR2009-013097-40-ES   Germany;Spain;United Kingdom
      2009   -   EUCTR2009-013097-40-DE   Germany;Spain;United Kingdom
NT 101
   Merz Pharmaceuticals GmbH
      2014   Phase 3   EUCTR2012-005539-10-DE   Germany;Poland;United States
PET/CT
   Kagawa University
      2021   -   JPRN-UMIN000043737   Japan
Pyruvate, creatine, niacinamide
   University of Louisville
      2004   -   NCT00605930   United States
Radiopharmaceuticals
   University of California, Berkeley
      2019   Early Phase 1   NCT03926702   United States
Rasagilin
   Klinikum der Universität München
      2010   -   EUCTR2008-007520-26-DE   Germany
Rasagiline
   Prof. Dr. Stefan Lorenzl
      2010   Phase 3   NCT01187888   Germany
Rasagiline mesilate
   Klinikum der Universität München
      2010   -   EUCTR2008-007520-26-DE   Germany
Riluzole
   King's College London
      2000   Phase 3   NCT00211224   United Kingdom
Rivastigmine
   Assistance Publique Hopitaux De Marseille
      2016   Phase 3   NCT02839642   France
   University Hospital Tuebingen
      2008   Phase 2   NCT00522015   Germany
   University of Tuebingen
      2007   -   EUCTR2006-006166-42-DE   Germany
RT001
   Retrotope, Inc
      2021   Phase 2   EUCTR2020-003911-90-SK   Germany;Hungary;Poland;Slovakia
      2021   Phase 2   EUCTR2020-003911-90-PL   Germany;Hungary;Poland;Slovakia
      2021   Phase 2   EUCTR2020-003911-90-HU   Germany;Hungary;Poland;Slovakia
      2021   Phase 2   EUCTR2020-003911-90-DE   Germany;Hungary;Poland;Slovakia
   Retrotope, Inc.
      2021   Phase 2   NCT04937530   Germany
Salsalate
   Adam Boxer
      2015   Phase 1   NCT02422485   United States
Single dose C2N-8e12
   C2N Diagnostics
      2015   Phase 1   NCT02494024   United States
Stem cell therapy
   Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
      2012   Phase 1/Phase 2   NCT01824121   Italy
Sugar pill
   Prof. Dr. Stefan Lorenzl
      2010   Phase 3   NCT01187888   Germany
Suvorexant
   University of California, San Francisco
      2019   Phase 4   NCT04014387   United States
THK-5351
   Kagawa University
      2021   -   JPRN-UMIN000043737   Japan
   Nagoya University Department of Neurology
      2015   -   JPRN-UMIN000018496   Japan
   Tohoku University Hospital
      2016   -   JPRN-UMIN000024541   Japan
THK5351
   Nagoya City Rehabilitation Agency
      2019   -   JPRN-UMIN000036956   Japan
Tideglusib
   Noscira SA
      2009   -   NCT01049399   Germany;Spain;United Kingdom;United States
Tolfenamic acid
   NeuroTau, Inc.
      2021   Phase 1/Phase 2   NCT04253132   United States
TPI 287 2 MG/M2
   University of California, San Francisco
      2014   Phase 1   NCT02133846   United States
TPI-287 20 MG/M2
   University of California, San Francisco
      2014   Phase 1   NCT02133846   United States
TPI-287 6.3 MG/M2
   University of California, San Francisco
      2014   Phase 1   NCT02133846   United States
TPN-101, 100 MG/DAY
   Transposon Therapeutics, Inc.
      2021   Phase 2   NCT04993768   United States
TPN-101, 200 MG/DAY
   Transposon Therapeutics, Inc.
      2021   Phase 2   NCT04993768   United States
TPN-101, 400 MG/DAY
   Transposon Therapeutics, Inc.
      2021   Phase 2   NCT04993768   United States
Trihexyphenidyl
   1) Department of Neurology, Gifu University Graduate School of Medicine, 2) National Hospital Organization, Higashi Nagoya Hospital
      2019   -   JPRN-UMIN000036522   Japan
Ubidecarenon
   Kompetenznetz Parkinson e.V.
      2006   -   EUCTR2005-000574-40-DE   Germany
Valproic acid
   Nantes University Hospital
      2006   Phase 2   NCT00385710   France
Vizamyl
   Skåne University Hospital
      2017   Phase 2   EUCTR2017-000094-36-SE   Sweden
Water
   Juntendo University School of Medicine, Department of Neurology
      2012   Phase 1   JPRN-UMIN000008959   Japan
Xeomin
   Merz Pharmaceuticals GmbH
      2014   Phase 3   EUCTR2012-005539-10-DE   Germany;Poland;United States
Zoledronic acid 5MG/BAG 100ML INJ
   California Pacific Medical Center Research Institute
      2019   Phase 4   NCT03924414   United States
Zolpidem
   University of California, San Francisco
      2019   Phase 4   NCT04014387   United States